These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21864230)

  • 1. The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics.
    Widler L; Jahnke W; Green JR
    Anticancer Agents Med Chem; 2012 Feb; 12(2):95-101. PubMed ID: 21864230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrogen-containing bisphosphonates and cancer immunotherapy.
    Clézardin P; Massaia M
    Curr Pharm Des; 2010; 16(27):3007-2014. PubMed ID: 20722623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
    Ebetino FH; Sun S; Cherian P; Roshandel S; Neighbors JD; Hu E; Dunford JE; Sedghizadeh PP; McKenna CE; Srinivasan V; Boeckman RK; Russell RGG
    Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
    Dunford JE
    Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.
    Roelofs AJ; Thompson K; Ebetino FH; Rogers MJ; Coxon FP
    Curr Pharm Des; 2010; 16(27):2950-60. PubMed ID: 20722616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ).
    Endo Y; Kumamoto H; Nakamura M; Sugawara S; Takano-Yamamoto T; Sasaki K; Takahashi T
    Biol Pharm Bull; 2017; 40(6):739-750. PubMed ID: 28566618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid - a multiplicity of anti-cancer action.
    Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
    Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
    Russell RG; Watts NB; Ebetino FH; Rogers MJ
    Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiology of the aging bone and mechanisms of action of bisphosphonates.
    Dominguez LJ; Di Bella G; Belvedere M; Barbagallo M
    Biogerontology; 2011 Oct; 12(5):397-408. PubMed ID: 21695491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates: from bench to bedside.
    Russell RG
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Introduction to bisphosphonates. History and functional mechanisms].
    Fleisch H
    Orthopade; 2007 Feb; 36(2):103-4, 106-9. PubMed ID: 17277961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates.
    van Beek ER; Cohen LH; Leroy IM; Ebetino FH; Löwik CW; Papapoulos SE
    Bone; 2003 Nov; 33(5):805-11. PubMed ID: 14623056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The backbone of progress--preclinical studies and innovations with zoledronic acid.
    Green JR; Guenther A
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S3-S12. PubMed ID: 21353178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
    Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RG; Oppermann U
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7829-34. PubMed ID: 16684881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.